Oxybutynin Reduces Hot Flashes in Men

A phase 2 study, featuring Mayo Clinic researchers including Bradley Stish, found that the medication Oxybutynin significantly reduced hot flashes in men undergoing hormone therapy for prostate cancer. The study, conducted through the Alliance for Clinical Trials in Oncology, enrolled 88 men and showed that those taking Oxybutynin experienced a notable decrease in the frequency and intensity of hot flashes compared to a placebo. Participants on a higher dose of Oxybutynin saw an average reduction of nearly seven hot flashes per day. Patients reported improved daily functioning and quality of life, with dry mouth as the most common side effect. This trial suggests Oxybutynin as a viable option for managing hot flashes in men on androgen-deprivation therapy, with researchers calling for larger studies to confirm findings and determine optimal dosage. Mayo Clinic has a financial interest in the technology.